Seer (NASDAQ:SEER) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Seer (NASDAQ:SEER) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04), FiscalAI reports. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.55 million. Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%.

Here are the key takeaways from Seer’s conference call:

• Revenue remained under pressure, with second-quarter revenue of $3.1 million versus $4.1 million a year earlier, due to weak academic and government funding and longer sales cycles. The company posted a $16.9 million net loss.
• Management reaffirmed full-year 2026 revenue guidance of $16 million to $18 million, citing stronger customer discussions, increased consumable pull-through, new commercial leadership, and anticipated population-scale study opportunities in the second half.
• Seer reported more than 95 publications, preprints, and reviews supporting the Proteograph platform, while independent studies highlighted its depth, reproducibility, and ability to identify proteins and genetic associations missed by competing assays.
• The company ended the quarter with $209.5 million in cash and investments, believes it has sufficient capital to reach cash-flow breakeven, and has repurchased approximately 13.4 million shares, reducing net shares outstanding by about 15%.
• Seer completed the first 10,000 samples of its PRECISE-SG100K population study and plans to present preliminary data at HUPO in September, while continuing discussions with potential large-scale cohort partners. Management views these results as a potential catalyst for larger buyback commitments and broader adoption.

Seer Stock Performance

NASDAQ:SEER remained flat at $2.16 during mid-day trading on Tuesday. The company’s stock had a trading volume of 202,072 shares, compared to its average volume of 644,578. Seer has a 1 year low of $1.55 and a 1 year high of $2.41. The stock has a market capitalization of $118.76 million, a price-to-earnings ratio of -1.74 and a beta of 1.55. The company has a fifty day moving average price of $1.94 and a two-hundred day moving average price of $1.88.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Canaccord Genuity Group initiated coverage on Seer in a report on Monday, May 4th. They set a “buy” rating and a $4.00 price objective for the company. TD Cowen raised shares of Seer to a “strong-buy” rating in a research note on Monday, April 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Seer in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $4.00.

Institutional Trading of Seer

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Seer by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company’s stock worth $4,820,000 after acquiring an additional 18,760 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in Seer by 15.5% in the second quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company’s stock valued at $1,792,000 after purchasing an additional 112,100 shares in the last quarter. Geode Capital Management LLC increased its stake in Seer by 16.5% in the second quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock valued at $1,091,000 after purchasing an additional 72,265 shares in the last quarter. Jane Street Group LLC raised its holdings in Seer by 33.3% in the first quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after purchasing an additional 63,432 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Seer by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company’s stock worth $431,000 after purchasing an additional 6,304 shares during the period. 75.20% of the stock is owned by institutional investors.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.